Wang M - Search Results

1

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.

Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma Z, Li X, Zhuang W, Liu Y, Li W, Cui J, Wang D, Liao W, Zhou J, Wang Z, Sun Y, Qiu X, Gao J, Bao Y, Liang L, Wang M. Lu S, et al. Among authors: wang j, wang z, wang m, wang d. J Thorac Oncol. 2021 Sep;16(9):1512-1522. doi: 10.1016/j.jtho.2021.05.005. Epub 2021 May 23. J Thorac Oncol. 2021. PMID: 34033975 Free article. Clinical Trial.

2

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.

Mu XL, Li LY, Zhang XT, Wang SL, Wang MZ. Mu XL, et al. BMC Cancer. 2004 Aug 19;4:51. doi: 10.1186/1471-2407-4-51. BMC Cancer. 2004. PMID: 15318946 Free PMC article. Clinical Trial.

3

[Efficacy and safety of gefitinib monotherapy for Chinese elderly patients with advanced non-small cell lung cancer].

Zhang L, Wang SL, Zhang XT, Li LY, Wang MZ. Zhang L, et al. Zhonghua Nei Ke Za Zhi. 2007 May;46(5):392-5. Zhonghua Nei Ke Za Zhi. 2007. PMID: 17637309 Chinese.

4

[Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis].

Wu C, Li LY, Wang MZ, Zhang L, Zhang XT, Zhong W, Wang SL, Wang HZ. Wu C, et al. Zhonghua Zhong Liu Za Zhi. 2007 Dec;29(12):943-5. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 18478938 Clinical Trial. Chinese.

5

[Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer].

Wang MZ, Zhong W, Zhang L, Li LY, Wang SL, Li JR, Zhang XT. Wang MZ, et al. Zhonghua Zhong Liu Za Zhi. 2008 Mar;30(3):221-4. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 18756941 Clinical Trial. Chinese.

6

[The efficacy and safety of pemetrexed as monotherapy for Chinese patients with advanced non-small cell lung cancer].

Zhong W, Zhao J, Zhang XT, Zhang L, Wang MZ, Li LY. Zhong W, et al. Zhonghua Nei Ke Za Zhi. 2010 Aug;49(8):671-4. Zhonghua Nei Ke Za Zhi. 2010. PMID: 20979786 Clinical Trial. Chinese.

7

Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small cell lung cancer.

Zhu YJ, Xia Y, Ren GJ, Wang MZ, Zeng X, Zhang L. Zhu YJ, et al. Chin Med J (Engl). 2010 Nov;123(22):3200-5. Chin Med J (Engl). 2010. PMID: 21163115

8

Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.

Wang HP, Zhang L, Wang YX, Tan FL, Xia Y, Ren GJ, Hu P, Jiang J, Wang MZ, Xiao Y. Wang HP, et al. Chin Med J (Engl). 2011 Jul 5;124(13):1933. Chin Med J (Engl). 2011. PMID: 22088449 Clinical Trial.

9

[Evaluation of efficacy and safety of bevacizumab combined with chemotherapy for Chinese patients with advanced non-small cell lung cancer].

Zhao X, Wang M, Zhang L, Li L, Zhong W. Zhao X, et al. Among authors: wang m. Zhongguo Fei Ai Za Zhi. 2012 Jan;15(1):6-10. doi: 10.3779/j.issn.1009-3419.2012.01.02. Zhongguo Fei Ai Za Zhi. 2012. PMID: 22237117 Free PMC article. Clinical Trial. Chinese.

10

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators. Zhang L, et al. Among authors: wang j, wang m. Lancet Oncol. 2012 May;13(5):466-75. doi: 10.1016/S1470-2045(12)70117-1. Epub 2012 Apr 17. Lancet Oncol. 2012. PMID: 22512843 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67,935 results

Search Page

Filters